Sarepta Therapeutics, Inc. provided revenue guidance for the full year of 2022. The company raised full year total revenue guidance to between $905 million and $920 million and net product revenue guidance to between $825 million and $840 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
122.8 USD | -1.73% | -0.39% | +27.39% |
Jun. 13 | Health Care Flat on Mixed Drug Developments - Health Care Roundup | DJ |
Jun. 03 | Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.39% | 11.61B | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+106.26% | 10.31B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Full Year of 2022